Pharmaceutical giant AstraZeneca $AZN.L has reaffirmed its 2025 sales outlook, signaling confidence in its long-term strategy even amid potential disruptions from looming U.S. tariffs on EU-manufactured drugs. CEO Pascal Soriot stated that the forecast remains intact—provided any new tariffs imposed by Washington align with those already applied across other sectors.